Trends in the Cost of Medicines, Consultation Fees and Clinic Visits in Malaysia’s Private Primary Healthcare System: Employer Health Insurance Coverage

References

• Danzon P, Mulcahy A, Towse AK, et al. Pharmaceutical pricing in emerging markets: effects of income, competition, and procurement. Health Econ. 2015;24(2):238–252. doi:10.1002/hec.3013
   PubMed Web of Science ®Google Scholar
• Danzon P, Towse A, Mestre-Ferrandiz J. Value-based differential pricing: efficient prices for drugs in a global context. Health Econ. 2015;24(3):294–301. doi:10.1002/hec.3021
   PubMed Web of Science ®Google Scholar
• Rahman MM, Zhang C, Swe KT, et al. Disease-specific out-of-pocket healthcare expenditure in urban Bangladesh: a Bayesian analysis. PLoS One. 2020;15(1):e0227565. doi:10.1371/journal.pone.0227565
   PubMed Web of Science ®Google Scholar
• Godman B, Fadare J, Kwon H-Y, et al. Evidence-based public policy making for medicines across countries: findings and implications for the future. J Comp Eff Res. 2021;10(12):1019–1052. doi:10.2217/cer-2020-0273
   PubMed Web of Science ®Google Scholar
• Swetha NB, Shobha S, Sriram S. Prevalence of catastrophic health expenditure and its associated factors, due to out-of-pocket health care expenses among households with and without chronic illness in Bangalore, India: a longitudinal study. J Prev Med Hyg. 2020;61(1):E92–E97. doi:10.15167/2421-4248/jpmh2020.61.1.1191
   PubMedGoogle Scholar
• Vuong QH, Ho TM, Nguyen HK, Vuong TT. Healthcare consumers’ sensitivity to costs: a reflection on behavioural economics from an emerging market. Palgrave Commun. 2018;4(1):1–10. doi:10.1057/s41599-018-0127-3
   Google Scholar
• Vuong Q-H. Sociodemographic factors influencing Vietnamese patient satisfaction with healthcare services and some meaningful empirical thresholds. Iran J Public Heal. 2018;47(1):119–126.
   PubMed Web of Science ®Google Scholar
• Luzzatto L, Hyry H, Schieppati A, et al. Outrageous prices of orphan drugs: a call for collaboration. Lancet. 2018;1(10149):31069. doi:10.1016/S0140-6736(18)31069-9
   Google Scholar
• Godman B, Hill A, Simoens S, et al. Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications. Expert Rev Pharmacoecon Outcomes Res. 2021;21(4):527–540. doi:10.1080/14737167.2021.1884546
   PubMed Web of Science ®Google Scholar
• The global use of medicine in 2019 and outlook to 2023; 2019. Available from: https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/the-global-use-of-medicine-in-2019-and-outlook-to-2023.pdf?_=1642424548771. Accessed June 12, 2023.
   Google Scholar
• See S. Malaysia’s healthcare expenditure to “increase considerably” in short term despite reforms: report. Singapore; 2021. Available from: https://www.businesstimes.com.sg/asean-business/malaysias-healthcare-expenditure-to-increase-considerably-in-short-term-despite. Accessed June 12, 2023.
   Google Scholar
• Fong MCC, Shanizza AIA. Malaysian statistics on medicine 2015–2016; 2020. Available from: https://www.pharmacy.gov.my/v2/sites/default/files/document-upload/malaysian-statistics-medicines-2015-2016.pdf. Accessed June 12, 2023.
   Google Scholar
• New Straights Times. Medical experts weigh in on 2021 budget; 2020. Available from: https://www.nst.com.my/news/nation/2020/11/638881/medical-experts-weigh-2021-budget. Accessed November 27, 2020.
   Google Scholar
• World Health Organization. A system of health accounts; 2011. Available from: https://www.who.int/health-accounts/methodology/sha2011.pdf?ua=1. Accessed November 27, 2020.
   Google Scholar
• Islands S. Asia pacific observatory on health systems and policies: Malaysia health system review. 2012.
   Google Scholar
• Rahim FF, Abdulrahman SA, Maideen SFK, Rashid A. Prevalence and factors associated with prediabetes and diabetes in fishing communities in Penang, Malaysia: a cross-sectional study. PLoS One. 2020;15(2):e0228570. doi:10.1371/journal.pone.0228570
   PubMed Web of Science ®Google Scholar
• Datamonitor Healthcare. Market access trends in the US, Europe, and emerging market; 2019. Available from: https://pharmaintelligence.informa.com/~/media/informa-shop-window/pharma/2019/files/whitepapers/global-market-access-whitepaper_.pdf. Accessed June 12, 2023.
   Google Scholar
• Kasonde L, Tordrup D, Naheed A, Zeng W, Ahmed S, Babar ZUD. Evaluating medicine prices, availability and affordability in Bangladesh using World Health Organisation and Health Action International methodology. BMC Health Serv Res. 2019;19(1):1–12. doi:10.1186/s12913-019-4221-z
   PubMedGoogle Scholar
• Hassali M, Shafie A, Babar Z, Khan T. A study comparing the retail drug prices between Northern Malaysia and Australia. J Pharm Heal Serv Res. 2012;3:103–107. doi:10.1111/j.1759-8893.2011.00080.x
   Google Scholar
• Wong SL, Ibrahim S, Kadir NA, Salleh SM. Access and affordability of medicines in Malaysia: need for a national pricing policy. Appl Health Econ Health Policy. 2019;17:641–654. doi:10.1007/s40258-019-00480-9
   PubMed Web of Science ®Google Scholar
• A price control headache; 2019. Available from: https://www.thestar.com.my/news/nation/2019/05/12/a-price-control-headache. Accessed April 11, 2020.
   Google Scholar
• Health ministry contemplating medicine price control; 2018. Available from: https://www.nst.com.my/news/nation/2018/07/391832/health-ministry-contemplating-medicine-price-control. Accessed April 11, 2020.
   Google Scholar
• Soleymani F, Godman B, Yarimanesh P, Kebriaeezadeh A. Prescribing patterns of physicians working in both the direct and indirect treatment sectors in Iran; findings and implications. J Pharm Heal Serv Res. 2019;10(4):407–413. doi:10.1111/jphs.12322
   Web of Science ®Google Scholar
• Ashigbie PG, Azameti D, Wirtz VJ. Challenges of medicines management in the public and private sector under Ghana’s National Health Insurance Scheme - a qualitative study. J Pharm Policy Pract. 2016;9(1):1–10. doi:10.1186/s40545-016-0055-9
   PubMedGoogle Scholar
• Goldacre B, Reynolds C, Powell-Smith A, et al. Do doctors in dispensing practices with a financial conflict of interest prescribe more expensive drugs? A cross-sectional analysis of English primary care prescribing data. BMJ Open. 2019;9(2):1–8. doi:10.1136/bmjopen-2018-026886
   PubMed Web of Science ®Google Scholar
• Jaafar S, Mohd Noh K, Abdul Muttalib K, Othman HJ. Malaysia Health System Review. Health Syst Transit. 2013;3(1):221.
   Google Scholar
• Godman B, Haque M, Kumar S, et al. Current utilization patterns for long-acting insulin analogues including biosimilars among selected Asian countries and the implications for the future. Curr Med Res Opin. 2021;37(9):1529–1545. doi:10.1080/03007995.2021.1946024
   PubMed Web of Science ®Google Scholar
• Rezal RS, Hassali MA, Alrasheedy AA, et al. Prescribing patterns for upper respiratory tract infections: a prescription-review of primary care practice in Kedah, Malaysia, and the implications. Expert Rev Anti Infect Ther. 2015;13(12):1547–1556. doi:10.1586/14787210.2015.1085303
   PubMed Web of Science ®Google Scholar
• O’Brien E. Employers’ benefits from workers’ health insurance. Milbank Q. 2003;81(1):5–43. doi:10.1111/1468-0009.00037
   PubMed Web of Science ®Google Scholar
• Viet Nguyen C. The impact of voluntary health insurance on healthcare utilization and out-of-pocket payments: new evidence for Vietnam. Heal Econ. 2012;21:946–966. doi:10.1002/hec.1768
   PubMed Web of Science ®Google Scholar
• Vuong QH. Be rich or don’t be sick: estimating Vietnamese patients’ risk of falling into destitution. Springerplus. 2015;4(1). doi:10.1186/s40064-015-1279-x
   PubMedGoogle Scholar
• Hassali MA, Kamil TKT, Yusof FAM, et al. General practitioners’ knowledge, attitude and prescribing of antibiotics for upper respiratory tract infections in Selangor, Malaysia: findings and implications. Expert Rev Anti Infect Ther. 2015;13(4):511–520. doi:10.1586/14787210.2015.1012497
   PubMed Web of Science ®Google Scholar
• Soleymani FGB, Yarimanesh PKA, Yarimanesh P, Kebriaeezadeh A. Prescribing patterns of physicians working in boqth the direct and indirect treatment sectors in Iran: findings and implications. J Pharm Heal Serv Res. 2019;10(4):407–413. doi:10.1111/jphs.12322
   Web of Science ®Google Scholar
• PMCare. About us. Available from: https://www.pmcare.com.my/about. Accessed March 31, 2020.
   Google Scholar
• International Islamic University Malaysia. Available from: https://en.wikipedia.org/wiki/International_Islamic_University_Malaysia. Accessed April 8, 2020.
   Google Scholar
• Zin CS, Taufek NH, Bux SH. Drug utilization and drug pricing in the private primary healthcare system in Malaysia: an employer price control mechanism. Front Public Heal. 2020;8:1–9. doi:10.3389/fpubh.2020.551328
   PubMed Web of Science ®Google Scholar
• StataCorp. Stata: Release 15. College Station, TX: StataCorp LLC; 2015.
   Google Scholar
• Joyce GF, Escarce JJ, Solomon MD, Goldman DP. Employer drug benefit plans and spending on prescription drugs. JAMA. 2002;288:1733–1740. doi:10.1001/jama.288.14.1733
   PubMed Web of Science ®Google Scholar
• Chan FKI, McGrail K, Majumdar SR, Law MR. Changes in employer-sponsored private health insurance among retirees in Ontario: a cross-sectional study. C Open. 2019;7(1):E15–E22. doi:10.9778/cmajo.20180067
   PubMedGoogle Scholar
• Bundorf MK. Employee demand for health insurance and employer health plan choices. J Health Econ. 2002;21(1):65–88. doi:10.1016/S0167-6296(01)00127-8
   PubMed Web of Science ®Google Scholar
• Vincent Rajkumar S. The high cost of prescription drugs: causes and solutions. Blood Cancer J. 2020;10(6). doi:10.1038/s41408-020-0338-x
   Web of Science ®Google Scholar
• Gonçalves R, Rodrigues V. Reference pricing with elastic demand for pharmaceuticals. Scand J Econ. 2018;120(1):159–182. doi:10.1111/sjoe.12207
   Web of Science ®Google Scholar
• Vuong Q-H, Le -T-T, Jin R, et al. Near-suicide phenomenon: an investigation into the psychology of patients with serious illnesses withdrawing from treatment. Int J Environ Res Public Health. 2023;20(6):5173. doi:10.3390/ijerph20065173
   PubMedGoogle Scholar
• Pillai V. Higher specialist fees expected, but curbed by competition; 2020. Available from: https://codeblue.galencentre.org/2020/01/17/higher-specialist-fees-expected-but-curbed-by-competition/. Accessed January 21, 2022.
   Google Scholar
• Motulsky A, Weir DL, Liang M, et al. Patient-initiated consultations in community pharmacies. Res Soc Adm Pharm. 2021;17(2):428–440. doi:10.1016/j.sapharm.2020.03.001
   PubMed Web of Science ®Google Scholar
• Fielding S, Porteous T, Ferguson J, et al. Estimating the burden of minor ailment consultations in general practices and emergency departments through retrospective review of routine data in North East Scotland. Fam Pract. 2015;32(2):165–172. doi:10.1093/fampra/cmv003
   PubMed Web of Science ®Google Scholar
• Cadogan CA, Hughes CM. On the frontline against COVID-19: community pharmacists’ contribution during a public health crisis. Res Soc Adm Pharm. 2021;17(1):2032–2035. doi:10.1016/j.sapharm.2020.03.015
   PubMed Web of Science ®Google Scholar
• Campbell SM, Meyer JC, Godman B. Why compliance to national prescribing guidelines is important especially across Sub-Saharan Africa and suggestions for the future. J Biomed Pharma Sci. 2021;4:35.
   Google Scholar
• Niaz Q, Godman B, Massele A, et al. Validity of World Health Organisation prescribing indicators in Namibia’s primary healthcare: findings and implications. Int J Qual Heal Care. 2019;31(5):338–345. doi:10.1093/intqhc/mzy172
   PubMed Web of Science ®Google Scholar
• Gustafsson LL, Wettermark B, Godman B, et al. The “wise list”- a comprehensive concept to select, communicate and achieve adherence to recommendations of essential drugs in ambulatory care in Stockholm. Basic Clin Pharmacol Toxicol. 2011;108(4):224–233. doi:10.1111/j.1742-7843.2011.00682.x
   PubMed Web of Science ®Google Scholar
• Eriksen J, Gustafsson LL, Ateva K, et al. High adherence to the “Wise List” treatment recommendations inStockholm: a 15-year retrospective review of a multifaceted approach promoting rational use of medicines. BMJ Open. 2017;7:e014345. doi:10.1136/bmjopen-2016-014345
   PubMed Web of Science ®Google Scholar
• Norman C, Zarrinkoub R, Hasselström J, Godman B, Granath F, Wettermark B. Potential savings without compromising the quality of care. Int J Clin Pract. 2009;63(9):1320–1326. doi:10.1111/j.1742-1241.2009.02129.x
   PubMed Web of Science ®Google Scholar
• Vogler S. Fair prices for medicines? Exploring competent authorities’ and public payers’ preferences on pharmaceutical policies. Empirica. 2019;46(3):443–469. doi:10.1007/s10663-019-09446-5
   Web of Science ®Google Scholar
• Vogler S, Zimmermann N, de Joncheere K. Policy interventions related to medicines: survey of measures taken in European countries during 2010–2015. Health Policy (New York). 2016;120(12):1363–1377. doi:10.1016/j.healthpol.2016.09.006
   Web of Science ®Google Scholar
• Danzon PM. Differential pricing of pharmaceuticals: theory, evidence and emerging issues. Pharmacoeconomics. 2018;36(12):1395–1405. doi:10.1007/s40273-018-0696-4
   PubMed Web of Science ®Google Scholar
• Hinsch M, Kaddar M, Schmitt S. Enhancing medicine price transparency through price information mechanisms. Glob Heal. 2014;10(34):54.
   PubMedGoogle Scholar
• Luiza V, Chaves L, Silva R, et al. Pharmaceutical policies: effects of cap and co-payment on rational use of medicines (Review) summary of findings for the main comparison. Cochrane Database Syst Rev. 2015;(5). doi:10.1002/14651858.CD007017
   PubMed Web of Science ®Google Scholar
• Van Woerkom M, Piepenbrink H, Godman B, et al. Ongoing measures to enhance the efficiency of prescribing of proton pump inhibitors and statins in the Netherlands: influence and future implications. J Comp Eff Res. 2012;1(6):527–538. doi:10.2217/cer.12.52
   PubMed Web of Science ®Google Scholar
• Macbride-stewart S, Mctaggart S, Kurdi A, et al. Initiatives and reforms across Scotland in recent years to improve prescribing, findings and global implications of drug prescriptions. PLoS One. 2021;14(12):2563–2586.
   Google Scholar